Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 829

1.

[Efficacy of omalizumab in patients with severe asthma using the asthma health questionnaire and asthma control test].

Saji J, Arai M, Yamamoto T, Mineshita M, Miyazawa T.

Arerugi. 2014 Dec;63(10):1338-47. Japanese.

PMID:
25634459
[PubMed - in process]
2.

The Use of Anti-IgE Therapy Beyond Allergic Asthma.

Stokes JR, Casale TB.

J Allergy Clin Immunol Pract. 2015 Jan 16. pii: S2213-2198(14)00507-8. doi: 10.1016/j.jaip.2014.10.010. [Epub ahead of print]

PMID:
25609342
[PubMed - as supplied by publisher]
3.

Severe asthma: definition, diagnosis and treatment.

Lommatzsch M, Virchow CJ.

Dtsch Arztebl Int. 2014 Dec 12;111(50):847-55. doi: 10.3238/arztebl.2014.0847.

PMID:
25585581
[PubMed - in process]
Free Article
4.

Severe Asthma: The Evolution of Patient-directed Management.

Keller M, Kamp D.

Clin Pulm Med. 2014 Jan 1;21(1):1-8.

PMID:
25580071
[PubMed]
Free PMC Article
5.

Omalizumab for Difficult-to-Treat Dermatological Conditions: Clinical and Immunological Features from a Retrospective Real-Life Experience.

Romano C, Sellitto A, De Fanis U, Balestrieri A, Savoia A, Abbadessa S, Astarita C, Lucivero G.

Clin Drug Investig. 2015 Jan 13. [Epub ahead of print]

PMID:
25578818
[PubMed - as supplied by publisher]
6.

The relationship between allergen immunotherapy and omalizumab for treating asthma.

Braido F, Corsico A, Rogkakou A, Ronzoni V, Baiardini I, Canonica GW.

Expert Rev Respir Med. 2015 Jan 12:1-6. [Epub ahead of print]

PMID:
25578528
[PubMed - as supplied by publisher]
7.

Anti-IgE Therapy: Clinical Utility and Mechanistic Insights.

Logsdon SL, Oettgen HC.

Curr Top Microbiol Immunol. 2015;388:39-61. doi: 10.1007/978-3-319-13725-4_3.

PMID:
25553794
[PubMed - in process]
8.

Cost-effectiveness of asthma therapy: A Comprehensive review.

Domínguez-Ortega J, Phillips-Anglés E, Barranco P, Quirce S.

J Asthma. 2014 Dec 24:1-23. [Epub ahead of print]

PMID:
25539023
[PubMed - as supplied by publisher]
9.

The impact of asthma exacerbations and preventive strategies.

Graham LM, Eidb N.

Curr Med Res Opin. 2014 Dec 22:1-35. [Epub ahead of print]

PMID:
25530129
[PubMed - as supplied by publisher]
10.

Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy.

Hendeles L, Khan YR, Shuster JJ, Chesrown SE, Abu-Hasan M.

Ann Allergy Asthma Immunol. 2015 Jan;114(1):58-62.e2. doi: 10.1016/j.anai.2014.10.012.

PMID:
25528738
[PubMed - in process]
11.

Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments.

Pelaia G, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Maselli R.

Curr Drug Targets. 2014 Dec 19. [Epub ahead of print]

PMID:
25523898
[PubMed - as supplied by publisher]
12.

Weekly low-dose methotrexate for reduction of Global Initiative for Asthma Step 5 treatment in severe refractory asthma: study protocol for a randomized controlled trial.

Polosa R, Bellinvia S, Caruso M, Emma R, Alamo A, Kowalski ML, Domingo C.

Trials. 2014 Dec 18;15:492. doi: 10.1186/1745-6215-15-492.

PMID:
25523634
[PubMed - in process]
Free PMC Article
13.

Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis.

Faria R, McKenna C, Palmer S.

Value Health. 2014 Dec;17(8):772-82. doi: 10.1016/j.jval.2014.07.009. Epub 2014 Oct 11.

PMID:
25498772
[PubMed - in process]
14.

Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE.

Lowe PJ, Georgiou P, Canvin J.

Regul Toxicol Pharmacol. 2015 Feb;71(1):68-77. doi: 10.1016/j.yrtph.2014.12.002. Epub 2014 Dec 8.

PMID:
25497995
[PubMed - in process]
Free Article
15.

Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.

Huffaker MF, Phipatanakul W.

Immunol Allergy Clin North Am. 2015 Feb;35(1):129-44. doi: 10.1016/j.iac.2014.09.005. Epub 2014 Nov 21.

PMID:
25459581
[PubMed - in process]
16.

Potential benefit of omalizumab in respiratory diseases.

Bonini M, Di Maria G, Paggiaro P, Rossi A, Senna G, Triggiani M, Canonica GW.

Ann Allergy Asthma Immunol. 2014 Nov;113(5):513-9. doi: 10.1016/j.anai.2014.06.031. Epub 2014 Nov 5.

PMID:
25442695
[PubMed - in process]
17.

The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy.

Namazy J, Cabana MD, Scheuerle AE, Thorp JM Jr, Chen H, Carrigan G, Wang Y, Veith J, Andrews EB.

J Allergy Clin Immunol. 2014 Oct 19. pii: S0091-6749(14)01198-1. doi: 10.1016/j.jaci.2014.08.025. [Epub ahead of print]

PMID:
25441639
[PubMed - as supplied by publisher]
18.

Allergic bronchopulmonary aspergillosis.

Greenberger PA, Bush RK, Demain JG, Luong A, Slavin RG, Knutsen AP.

J Allergy Clin Immunol Pract. 2014 Nov-Dec;2(6):703-8. doi: 10.1016/j.jaip.2014.08.007. Epub 2014 Nov 6.

PMID:
25439360
[PubMed - in process]
19.

Omalizumab in children.

Licari A, Marseglia A, Caimmi S, Castagnoli R, Foiadelli T, Barberi S, Marseglia GL.

Paediatr Drugs. 2014 Dec;16(6):491-502. doi: 10.1007/s40272-014-0107-z.

PMID:
25404353
[PubMed - in process]
Free PMC Article
20.

Omalizumab treatment in patient with severe Asthma and Eosinophilic Granulomatosis with Polyangiitis. A case report.

Graziani A, Quercia O, Girelli F, Martelli A, Mirici Cappa F, Stefanini GF.

Eur Ann Allergy Clin Immunol. 2014 Nov;46(6):226-8.

PMID:
25398166
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk